Related Experiment Video
Updated: Jan 6, 2026

Probiotic Studies in Neonatal Mice Using Gavage
Published on: January 27, 2019
Safety and tolerance of infant formulas containing probiotics: a multicenter, randomised, controlled trial in healthy
M Mitra1, A Petit-Jean2, R Agrawal3
1Department of Pediatrics, Institute of Child Health, Kolkata, India.
Insights
Infant formula with Limosilactobacillus reuteri or Bifidobacterium lactis probiotics showed non-inferior weight gain compared to standard formula. These probiotic formulas were safe and well-tolerated in healthy term infants.
Area of Science:
- Pediatric Nutrition
- Microbiome Research
- Clinical Trials
Background:
- Probiotic safety and tolerance in infants are documented, primarily with supplements.
- Limited data exists on probiotics integrated into infant formula for growth evaluation.
- This study addresses the need for evidence on formula-based probiotics in early life.
Purpose of the Study:
- To evaluate the non-inferiority of infant growth fed formula supplemented with Limosilactobacillus reuteri DSM17938 or Bifidobacterium lactis CNCM I-3446 compared to standard formula.
- To assess anthropometric measurements, digestive tolerance, and gut microbiota changes.
- To confirm the safety and tolerance of these probiotic-supplemented formulas.
Main Methods:
- Randomized, double-blind, multicenter trial involving healthy term infants.
- Three formula groups: L. reuteri, B. lactis, and standard formula (n=92 each).
- Exclusively breastfed infants (n=100) included for reference; mixed feeding allowed.
Main Results:
- Non-inferior weight gain was observed for both L. reuteri and B. lactis groups compared to the standard formula at 6 months.
- No significant differences in length, BMI, or head circumference z-scores, except for a slight decrease in weight-for-age z-score for B. lactis at 8 months.
- Similar adverse events and digestive tolerance reported across all formula groups; higher fecal L. reuteri counts in the L. reuteri group.
Conclusions:
- Infant formula supplemented with L. reuteri DSM17938 or B. lactis CNCM I-3446 supports non-inferior growth in term infants up to 6 months.
- Both probiotic formulas demonstrated safety and good tolerance, comparable to standard formula and breastfed infants.
- These findings support the use of specific probiotics within infant formula for healthy growth and tolerance.
Abstract:
Several studies have documented the safety and tolerance of probiotics in infants, however, most studies have been conducted with supplements. This randomised, double-blind, multicenter trial evaluated growth of healthy term infants fed infant formula supplemented with Limosilactobacillus reuteri DSM17938 (L. reuteri; n = 92) or Bifidobacterium lactis CNCM I-3446 (B. lactis; n = 92) or the same formula without probiotics ( n = 95). Mixed feeding with breast milk was allowed in each group. Exclusively breastfed infants ( n = 100) were included for reference. Non-inferiority in weight gain (margin -3 g/day) from enrolment to age 6 months was the primary outcome. Length, BMI, head circumference, and WHO z-scores from birth to 12 months were assessed, as was digestive tolerance, and, in a subset of infants, urinary D-lactate parameters and abundance of key bacteria in fecal matter. Of 279 infants randomised, 256 completed the study. The mean difference in weight gain between each probiotic group and the standard group at age 6 months was -0.378 g/day (97.5% confidence interval (CI), -1.541, 0.776; P < 0.001) for L. reuteri and -1.724 g/day (97.5% CI, -2.845, -0.603; P = 0.005) for B. lactis, indicating non-inferior growth. Anthropometric z-scores were not significantly different between any of the formulas, over the entire study, except for a slightly lower weight-for-age z-score in the B. lactis vs standard group at 8 months ( P = 0.034). No differences in adverse events or urinary D-lactate levels were observed. Significantly higher fecal lactobacilli counts were observed with L. reuteri supplementation ( 7.0 log 10 (CFU/g); n = 24) compared with standard formula ( 6.2 log 10 (CFU/g); n = 21). Parent-reported digestive tolerance symptoms were similar between the formula groups and comparable to the breastfed group. Weight gain from enrolment to age 6 months in infants fed formula containing probiotics L. reuteri DSM17938 or B. lactis CNCM I-3446 was non-inferior versus infants fed the same formula without probiotics. Both probiotic formulas were safe and well-tolerated.
More Related Videos
04:16Individualized Reconstitution of Human Milk Microbiota: A Feasible Approach in Real-World Settings
Published on: February 7, 2025
04:53A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Related Concept Videos
Bioavailability Study Design: Healthy Subjects Versus Patients
Drug Dosing: Infants and Children
Bioavailability Study Design: Single Versus Multiple Dose Studies
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Teratogenicity
Bioavailability Study Design: Absolute Versus Relative Bioavailability